Bone marrow disorder

Summary

Bone marrow disorder (MONDO:0003225) is a disease (an umbrella term covering 7 Mondo subtypes) and 23 clinical trials. Top therapeutic interventions include imatinib, lidocaine hydrochloride, and pacritinib. A subtype of immune system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 23

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bone marrow disorder
Mondo ID	MONDO:0003225
MeSH	D001855
DOID	DOID:4961
NCIT	C34433
SNOMED CT	127035006
UMLS	C4021634
MedGen	892905
GARD	0023414
Anatomy (UBERON)	UBERON:0002371
Is cancer (heuristic)	no

Also known as: bone marrow disease · bone marrow disease or disorder · bone marrow disorder · disease of bone marrow · disease or disorder of bone marrow · disorder of bone marrow

Disease family

This is a subtype of immune system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › bone marrow disorder

Related subtypes (46): hypersensitivity reaction disease, immune system cancer, immune system organ benign neoplasm, thymus gland disorder, inborn error of immunity, leukocyte disorder, psoriasis, spondyloarthropathy, aggressive insulitis, benign insulitis, inflammatory bowel disease, autoimmune disease, TNF receptor 1-associated periodic fever syndrome, epidermodysplasia verruciformis, Vici syndrome, proteosome-associated autoinflammatory syndrome, hyperimmunoglobulinemia D with periodic fever, transcobalamin II deficiency, pyogenic arthritis-pyoderma gangrenosum-acne syndrome, granulomatosis with polyangiitis, autosomal recessive osteopetrosis 7, graft versus host disease, congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome, Roifman syndrome, cryopyrin-associated periodic syndrome, anti-HLA hyperimmunization, acquired immunodeficiency, erythroderma desquamativum, autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis, familial Mediterranean fever, 22q11.2 deletion syndrome, T-cell large granular lymphocyte leukemia, twin to twin transfusion syndrome, immunodeficiency disease, immunoproliferative disorder, cytokine receptor deficiency, immunodeficiency-related disorder, phagocytic cell dysfunction, thrombocytopenic purpura, lymphoid system disorder, immune reconstitution inflammatory syndrome, growth hormone insensitivity with immune dysregulation 1, autosomal recessive, cytokine release syndrome, early-onset autoimmunity-autoinflammation-immunodeficiency syndrome, CADINS disease, autoinflammation, panniculitis, and dermatosis syndrome

Subtypes (7): bone marrow failure syndrome, osteomyelitis, bone marrow neoplasm, polycythemia, Fanconi anemia, Drachtman Weinblatt Sitarz syndrome, premature ovarian failure 15

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 23.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	11
PHASE2	4
PHASE1/PHASE2	3
PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00187135	PHASE3	TERMINATED	Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
NCT01511289	PHASE3	COMPLETED	Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
NCT06594965	PHASE2	NOT_YET_RECRUITING	A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT07387354	PHASE1/PHASE2	NOT_YET_RECRUITING	Pacritinib With Aza for Upfront Myelodysplastic Syndrome
NCT00113893	PHASE2	COMPLETED	SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
NCT00486720	PHASE2	TERMINATED	Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
NCT01762514	PHASE2	UNKNOWN	A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
NCT01787552	PHASE1/PHASE2	COMPLETED	A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
NCT02158858	PHASE1/PHASE2	COMPLETED	A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
NCT03773393	PHASE1	ACTIVE_NOT_RECRUITING	A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
NCT01629082	PHASE1	COMPLETED	Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT03066648	PHASE1	COMPLETED	Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
NCT05732870	Not specified	RECRUITING	OSTEOMICS: Identifying Regulators of Bone Homeostasis
NCT06703138	Not specified	NOT_YET_RECRUITING	Role of Diffusion MRI in Differentiation of Various Bone Marrow Lesions
NCT07102849	Not specified	ENROLLING_BY_INVITATION	Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study
NCT00001627	Not specified	COMPLETED	Collection of Blood and Bone Marrow From Healthy Volunteers and Patients for Research Purposes
NCT00085670	Not specified	COMPLETED	Cytokine Gene Polymorphisms in Bone Marrow Failure
NCT01928017	Not specified	COMPLETED	Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia
NCT03219125	Not specified	COMPLETED	Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women
NCT03492749	Not specified	COMPLETED	Busulfan Concentration in Saliva and Plasma, and Its Relationship With Salivary Changes and Mucositis in the Digestive Tract of Patients Submitted to Hematopoietic Stem Cell Transplantation
NCT04804631	Not specified	COMPLETED	Tube Feeding in Children Having a Bone Marrow Transplant
NCT05895357	Not specified	COMPLETED	The Effect of Music Therapy on Comfort, Pain and Anxiety
NCT05978583	Not specified	COMPLETED	Impact of Physical and Occupational Therapy in New BMT Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IMATINIB	4	1
LIDOCAINE HYDROCHLORIDE	4	1
PACRITINIB	4	1
RUXOLITINIB	4	1
SONIDEGIB	4	1
VORINOSTAT	4	1
PELABRESIB	3	1
RADOTINIB	3	1
SABATOLIMAB	3	1
SPARTALIZUMAB	3	1
TALMAPIMOD	2	1
CHEMBL4778465	0	1